{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:44:22Z","timestamp":1790390662637,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shield Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with standard oral irons is limited by poor absorption and gastrointestinal toxicity. Ferric maltol is an oral iron designed for improved absorption and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, phase 3b trial (EudraCT 2015-002496-26 and NCT02680756), adults with nonseverely active inflammatory bowel disease and iron-deficiency anemia (hemoglobin, 8.0-11.0\/12.0 g\/dL [women\/men]; ferritin, &amp;lt;30 ng\/mL\/&amp;lt;100 ng\/mL with transferrin saturation &amp;lt;20%) were randomized to oral ferric maltol 30 mg twice daily or intravenous ferric carboxymaltose given according to each center\u2019s standard practice. The primary endpoint was a hemoglobin responder rate (\u22652 g\/dL increase or normalization) at week 12, with a 20% noninferiority limit in the intent-to-treat and per-protocol populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the intent-to-treat (ferric maltol, n\u2005=\u2005125\/ferric carboxymaltose, n\u2005=\u2005125) and per-protocol (n\u2005=\u200578\/88) analyses, week 12 responder rates were 67% and 68%, respectively, for ferric maltol vs 84% and 85%, respectively, for ferric carboxymaltose. As the confidence intervals crossed the noninferiority margin, the primary endpoint was not met. Mean hemoglobin increases at weeks 12, 24, and 52 were 2.5 vs 3.0 g\/dL, 2.9 vs 2.8 g\/dL, and 2.7 vs 2.8 g\/dL with ferric maltol vs ferric carboxymaltose. Treatment-emergent adverse events occurred in 59% and 36% of patients, respectively, and resulted in treatment discontinuation in 10% and 3% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ferric maltol achieved clinically relevant increases in hemoglobin but did not show noninferiority vs ferric carboxymaltose at week 12. Both treatments had comparable long-term effectiveness for hemoglobin and ferritin over 52 weeks and were well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izab073","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:36:57Z","timestamp":1620974217000},"page":"373-384","source":"Crossref","is-referenced-by-count":34,"title":["Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9830-9126","authenticated-orcid":false,"given":"Stefanie","family":"Howaldt","sequence":"first","affiliation":[{"name":"Research Institute for IBD\u2013HaFCED e.K. , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Hep\u00e1ticas y Digestivas , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Martinez","sequence":"additional","affiliation":[{"name":"Gastroenterology Research of America , San Antonio , Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, Endocrinology, Diabetology, and Infectious Diseases, Klinikum Fulda , Fulda , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice Minden and University Hospital Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine I , Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"2023112422430295000_CIT0001","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.12493","article-title":"The management of iron deficiency in inflammatory bowel disease\u2014an online tool developed by the RAND\/UCLA appropriateness method","volume":"38","author":"Reinisch","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112422430295000_CIT0002","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrgastro.2010.151","article-title":"Diagnosis and management of iron deficiency anemia in patients with IBD","volume":"7","author":"Stein","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2023112422430295000_CIT0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/nu10010082","article-title":"Rational management of iron-deficiency anaemia in inflammatory bowel disease","volume":"10","author":"Nielsen","year":"2018","journal-title":"Nutrients"},{"key":"2023112422430295000_CIT0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000496966","article-title":"Safety of oral and intravenous iron","volume":"142","author":"DeLoughery","year":"2019","journal-title":"Acta Haematol."},{"key":"2023112422430295000_CIT0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s13318-016-0334-5","article-title":"Randomized open-label phase 1 study of the pharmacokinetics of ferric maltol in inflammatory bowel disease patients with iron deficiency","volume":"42","author":"Bokemeyer","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"2023112422430295000_CIT0006","author":"Advanz Pharma","year":"2016"},{"key":"2023112422430295000_CIT0007","author":"Kent Pharmaceuticals Ltd","year":"2019"},{"key":"2023112422430295000_CIT0008","author":"Ranbaxy (UK) Limited","year":"2019"},{"key":"2023112422430295000_CIT0009","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.crohns.2014.01.011","article-title":"Iron treatment and inflammatory bowel disease: what happens in real practice?","volume":"8","author":"Lugg","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2023112422430295000_CIT0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2023112422430295000_CIT0011","doi-asserted-by":"crossref","first-page":"f4822","DOI":"10.1136\/bmj.f4822","article-title":"Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials","volume":"347","author":"Litton","year":"2013","journal-title":"Bmj."},{"key":"2023112422430295000_CIT0012","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"2023112422430295000_CIT0013","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.2042-7158.1990.tb05408.x","article-title":"The importance of reductive mechanisms for intestinal uptake of iron from ferric maltol and ferric nitrilotriacetic acid (NTA)","volume":"42","author":"Barrand","year":"1990","journal-title":"J Pharm Pharmacol."},{"key":"2023112422430295000_CIT0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2257.1989.tb00222.x","article-title":"Absorption of ferric maltol, a novel ferric iron compound, in iron-deficient subjects","volume":"11","author":"Kelsey","year":"1989","journal-title":"Clin Lab Haematol."},{"key":"2023112422430295000_CIT0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2710.1991.tb00292.x","article-title":"Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test","volume":"16","author":"Kelsey","year":"1991","journal-title":"J Clin Pharm Ther."},{"key":"2023112422430295000_CIT0016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.2042-7158.1987.tb06249.x","article-title":"Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine","volume":"39","author":"Barrand","year":"1987","journal-title":"J Pharm Pharmacol."},{"key":"2023112422430295000_CIT0017","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/0006-2952(88)90556-4","article-title":"Characteristics of iron (III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol","volume":"37","author":"Levey","year":"1988","journal-title":"Biochem Pharmacol."},{"key":"2023112422430295000_CIT0018","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1476-5381.1991.tb12187.x","article-title":"Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat","volume":"102","author":"Barrand","year":"1991","journal-title":"Br J Pharmacol."},{"key":"2023112422430295000_CIT0019","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1991.tb12240.x","article-title":"Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat","volume":"102","author":"Barrand","year":"1991","journal-title":"Br J Pharmacol."},{"key":"2023112422430295000_CIT0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MIB.0000000000000314","article-title":"Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program","volume":"21","author":"Gasche","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2023112422430295000_CIT0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.13665","article-title":"Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study","volume":"44","author":"Schmidt","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112422430295000_CIT0022","author":"World Health Organization, Vitamin and Mineral Nutrition Information System","year":"2011"},{"key":"2023112422430295000_CIT0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ijlh.13160","article-title":"Distribution of hemoglobin levels and prevalence of anemia according to sex, age group, and region in 13 Korean cities","volume":"42","author":"Nah","year":"2020","journal-title":"Int J Lab Hematol."},{"key":"2023112422430295000_CIT0024","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.drudis.2015.07.005","article-title":"Addressing unmet needs in inflammatory bowel disease","volume":"20","author":"Bokemeyer","year":"2015","journal-title":"Drug Discov Today."},{"key":"2023112422430295000_CIT0025","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/j.1572-0241.2005.00250.x","article-title":"Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease\u2014a randomized, controlled, open-label, multicenter study","volume":"100","author":"Schr\u00f6der","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"2023112422430295000_CIT0026","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1572-0241.2007.01744.x","article-title":"A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial","volume":"103","author":"Kulnigg","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"2023112422430295000_CIT0027","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/00365520902839667","article-title":"Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study","volume":"44","author":"Lindgren","year":"2009","journal-title":"Scand J Gastroenterol."},{"key":"2023112422430295000_CIT0028","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/ajg.2013.335","article-title":"A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)","volume":"108","author":"Reinisch","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"2023112422430295000_CIT0029","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/apt.14043","article-title":"Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease","volume":"45","author":"Aksan","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112422430295000_CIT0030","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev","year":"2011","journal-title":"Gastroenterology."},{"key":"2023112422430295000_CIT0031","doi-asserted-by":"crossref","first-page":"e02045","DOI":"10.1016\/j.heliyon.2019.e02045","article-title":"Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations","volume":"5","author":"Rostoker","year":"2019","journal-title":"Heliyon."},{"key":"2023112422430295000_CIT0032","author":"European Medicines Agency","year":"1998"},{"key":"2023112422430295000_CIT0033","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jacc.2015.10.051","article-title":"Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"2023112422430295000_CIT0034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials."},{"key":"2023112422430295000_CIT0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/CVM-1-1-019","article-title":"Noninferiority trials","volume":"1","author":"Snapinn","year":"2000","journal-title":"Curr Control Trials Cardiovasc Med."},{"key":"2023112422430295000_CIT0036","doi-asserted-by":"crossref","first-page":"e012594","DOI":"10.1136\/bmjopen-2016-012594","article-title":"Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals","volume":"6","author":"Rehal","year":"2016","journal-title":"BMJ Open."},{"key":"2023112422430295000_CIT0037","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjmed.2017.03.023","article-title":"The intention-to-treat analysis is not always the conservative approach","volume":"130","author":"Shrier","year":"2017","journal-title":"Am J Med."},{"key":"2023112422430295000_CIT0038","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3945\/ajcn.112.040626","article-title":"Effect of iron intake on iron status: a systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Casgrain","year":"2012","journal-title":"Am J Clin Nutr."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/3\/373\/53787701\/izab073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/3\/373\/53787701\/izab073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T18:18:28Z","timestamp":1700849908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/3\/373\/6275616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,5,14]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab073","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,5,14]]}}}